Envoy Medical (COCH) Cash & Equivalents (2020 - 2026)

Envoy Medical has reported Cash & Equivalents for 7 years, with the latest figure at $25.3 million in Q1 2026.

• Quarterly Cash & Equivalents rose 375.36% year-over-year to $25.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.3 million (up 375.36% YoY) and the FY2025 annual result came in at $3.7 million, down 31.81% from the prior year.
• Cash & Equivalents grew to $25.3 million in Q1 2026 per COCH's latest filing, from $3.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $25.3 million in Q1 2026 and troughed at $68000.0 in Q2 2023.
• A 5-year average of $5.2 million and a median of $4.0 million in 2023 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 5476.21% in 2023, down 85.74% in 2023.
• Over 5 years, Cash & Equivalents stood at $183000.0 in 2022, then jumped by 2205.46% to $4.2 million in 2023, then rose by 29.96% to $5.5 million in 2024, then sank by 31.81% to $3.7 million in 2025, then surged by 575.34% to $25.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $25.3 million, $3.7 million, and $3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.